United Therapeutics Corporation (UTHR) Return on Invested Capital (ROIC): 16.14%
Is United Therapeutics Corporation’s return on invested capital (ROIC) high or low?
United Therapeutics Corporation's return on invested capital (ROIC) of 16.14% is 23% above its 5-year average of 13.09%, near the high end of its 5-year range (9.16%–16.14%).
As of Saturday, June 13, 2026. 2.22% above its 12-month average of 15.79%.
UTHR Return on Invested Capital (ROIC) Chart
UTHR Average Return on Invested Capital (ROIC) Chart
UTHR Current vs Average Return on Invested Capital (ROIC) Chart
UTHR Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
16.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
15.79%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.57%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
13.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
15.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
15.98%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
13.11%
CURRENT VS TTM AVG
+2.22%
CURRENT VS 3Y AVG
+10.79%
CURRENT VS 5Y AVG
+23.25%
CURRENT VS 10Y AVG
+1.83%
CURRENT VS 15Y AVG
+1.02%
CURRENT VS 20Y AVG
+23.09%
UTHR Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 16.14% | 15.79% | 14.57% | 13.09% |
| Waters Corporation (WAT) | $23.17B | 17.57% | 18.00% | 20.73% | 22.79% |
| BioNTech SE (BNTX) | $22.90B | -3.14% | -4.79% | 9.55% | 20.42% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 35.46% | 38.26% | 37.51% | 36.01% |
| Labcorp Holdings Inc. (LH) | $21.83B | 7.39% | 6.30% | 5.64% | 7.56% |
| Veeva Systems Inc. (VEEV) | $25.92B | 9.48% | 9.25% | 9.54% | 11.31% |
| Moderna, Inc. (MRNA) | $19.80B | -29.70% | -31.12% | -12.69% | 0.19% |
| DexCom, Inc. (DXCM) | $29.08B | 16.61% | 13.40% | 11.07% | 9.62% |
| Hologic, Inc. (HOLX) | $16.97B | 7.35% | 8.59% | 9.78% | 13.56% |
| Biogen Inc. (BIIB) | $29.53B | 6.62% | 7.71% | 8.64% | 10.90% |
Capital Efficiency
ROIC
16.1%
ROE
21.8%
United Therapeutics Corporation Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The return on invested capital (ROIC) for UTHR stock is 16.14%.
- Is United Therapeutics Corporation's return on invested capital (ROIC) high or low?
- United Therapeutics Corporation's return on invested capital (ROIC) of 16.14% is 23% above its 5-year average of 13.09%, near the high end of its 5-year range (9.16%–16.14%).
- What is the TTM average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The TTM average return on invested capital (ROIC) for UTHR stock is 15.79%.
- What is the 3Y average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The 3Y average return on invested capital (ROIC) for UTHR stock is 14.57%.
- What is the 5Y average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The 5Y average return on invested capital (ROIC) for UTHR stock is 13.09%.
- What is the 10Y average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The 10Y average return on invested capital (ROIC) for UTHR stock is 15.85%.
- What is the 15Y average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The 15Y average return on invested capital (ROIC) for UTHR stock is 15.98%.
- What is the 20Y average return on invested capital (ROIC) for United Therapeutics Corporation (UTHR)?
- The 20Y average return on invested capital (ROIC) for UTHR stock is 13.11%.
United Therapeutics Corporation Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 16.14% |
| 2024-12-31 | 15.44% |
| 2023-12-31 | 13.54% |
| 2022-12-31 | 13.15% |
| 2021-12-31 | 9.16% |
| 2020-12-31 | 11.14% |
| 2019-12-31 | -3.21% |
| 2018-12-31 | 20.01% |
| 2017-12-31 | 18.18% |
| 2016-12-31 | 35.86% |
| 2015-12-31 | 24.94% |
| 2014-12-31 | 23.16% |
| 2013-12-31 | 10.88% |
| 2012-12-31 | 20.09% |
| 2011-12-31 | 17.68% |
| 2010-12-31 | 9.48% |
| 2009-12-31 | 2.76% |
| 2008-12-31 | -5.97% |
| 2007-12-31 | 1.12% |
| 2006-12-31 | 6.31% |
| 2005-12-31 | 15.49% |
| 2004-12-31 | 6.83% |
| 2003-12-31 | -6.79% |
| 2002-12-31 | -10.27% |
| 2001-12-31 | -17.27% |
| 2000-12-31 | -31.74% |
| 1999-12-31 | -60.46% |
| 1998-12-31 | -78.70% |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt